A detailed history of Legal & General Group PLC transactions in Maxcyte, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 107,472 shares of MXCT stock, worth $441,709. This represents 0.0% of its overall portfolio holdings.

Number of Shares
107,472
Previous 107,472 -0.0%
Holding current value
$441,709
Previous $418,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.68 - $5.06 $14,267 - $19,617
3,877 Added 3.74%
107,472 $418,000
Q2 2024

Aug 14, 2024

BUY
$3.63 - $5.0 $68,835 - $94,815
18,963 Added 22.41%
103,595 $406,000
Q1 2024

May 14, 2024

BUY
$3.94 - $5.38 $15,011 - $20,497
3,810 Added 4.71%
84,632 $354,000
Q4 2023

Feb 15, 2024

BUY
$2.6 - $5.24 $17,466 - $35,202
6,718 Added 9.07%
80,822 $379,000
Q3 2023

Nov 14, 2023

BUY
$3.02 - $5.1 $43,149 - $72,868
14,288 Added 23.89%
74,104 $231,000
Q2 2023

Aug 14, 2023

BUY
$3.69 - $5.35 $115,526 - $167,497
31,308 Added 109.82%
59,816 $274,000
Q1 2023

May 15, 2023

BUY
$4.03 - $5.89 $7,193 - $10,513
1,785 Added 6.68%
28,508 $141,000
Q4 2022

Feb 14, 2023

BUY
$4.92 - $7.4 $5,653 - $8,502
1,149 Added 4.49%
26,723 $145,000
Q3 2022

Nov 14, 2022

SELL
$4.52 - $6.51 $787,718 - $1.13 Million
-174,274 Reduced 87.2%
25,574 $166,000
Q2 2022

Aug 22, 2022

SELL
$3.59 - $6.81 $7,402 - $14,042
-2,062 Reduced 1.02%
199,848 $942,000
Q1 2022

May 16, 2022

SELL
$5.26 - $10.84 $1.08 Million - $2.23 Million
-205,552 Reduced 50.45%
201,910 $1.43 Million
Q4 2021

Feb 14, 2022

SELL
$8.87 - $12.94 $3.93 Million - $5.73 Million
-443,174 Reduced 52.1%
407,462 $4.16 Million
Q3 2021

Nov 15, 2021

BUY
$12.21 - $17.2 $10.4 Million - $14.6 Million
850,636 New
850,636 $10.4 Million

Others Institutions Holding MXCT

About MAXCYTE, INC.


  • Ticker MXCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 101,724,000
  • Market Cap $418M
  • Description
  • MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...
More about MXCT
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.